Funded Projects
Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.
Project # | Project Title | Research Focus Area | Research Program | Administering IC | Institution(s) | Investigator(s) | Location(s) | Year Awarded |
---|---|---|---|---|---|---|---|---|
1UG3DA059286-01
Show Summary |
A Therapeutic Agent to Lower the Level of Synthetic Opioids in the Body | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | CLEAR SCIENTIFIC, LLC | LI, XINHUA | Cambridge, MA | 2023 |
NOFO Title: Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
NOFO Number: PAR-22-200 Summary: There is an urgent need for longer acting opioid overdose reversal medications to treat acute fentanyl intoxication and overdose. This project will develop a novel molecule (CS-1103) that sticks to fentanyl and removes it from the body. Previous research with animal models shows that CS-1103 has several features that make it attractive for a new medication. It can reverse fentanyl-induced respiratory depression, preventing another overdose; work in combination with naloxone; and appears to be safe and well-tolerated. The research will continue exploration of CS-1103 toward testing CS-1103 in human research participants. |
||||||||
1R61NS131307-01
Show Summary |
Preclinical Assessment of a Novel Systemic Drug Candidate for Osteoarthritic Pain | Preclinical and Translational Research in Pain Management | Development and Optimization of Non-Addictive Therapies to Treat Pain | NINDS | UNIVERSITY OF SOUTHERN CALIFORNIA | EVSEENKO, DENIS | Los Angeles, CA | 2023 |
NOFO Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
NOFO Number: PAR-20-092 Summary: Osteoarthritis is a degenerative joint disease marked by progressively worsening chronic joint pain that affects function and quality of life. Non-opioid, alternative medications are needed for people with this condition. Joint inflammation, damage, and pain involve signaling through the interleukin-6/glycoprotein 130 pathway. This project will test blocking this pathway in rodents with a new molecule with improved drug-like properties, toward developing an oral medication for osteoarthritis. |
||||||||
3R01DA057605-01S1
Show Summary |
Diversity Supplement - Rapid Actionable Data for Opioid Response in Kentucky (RADOR-KY) | Cross-Cutting Research | Increasing Participant Diversity, Inclusion, and Engagement in HEAL Research | NIDA | UNIVERSITY OF KENTUCKY | SLAVOVA, SVETLA STEFANOVA (contact); TALBERT, JEFFERY C | Lexington, KY | 2023 |
NOFO Title: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
NOFO Number: NOT-NS-20-107 Summary: RADOR-KY is a near real-time, state-wide surveillance system to monitor prevention and treatment services for opioid use disorder (OUD). This project will fill gaps in this system by capturing data from agencies receiving state funding to provide treatment and support services for people with OUD. Access to the additional data will help expand and improve surveillance dashboards being used to coordinate and target resources for preventing overdose deaths. |
||||||||
1UG3DA058439-01
Show Summary |
Transcutaneous Phrenic Nerve Stimulation for Treating Opioid Overdose | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | CORIDEA, LLC | LEVIN, HOWARD (contact); COMER, SANDRA D; GUEDES, ALONSO; WAGENER, GEBHARD | New York, NY | 2023 |
NOFO Title: Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)
NOFO Number: PAR-20-279 Summary: Difficulty breathing is a hallmark symptom of an opioid-related overdose and can result in permanent brain injury or death within minutes. This project will develop a community-deployable Automated External Respiration System device that can restore and sustain breathing in people experiencing opioid-induced respiratory depression. The device stimulates the phrenic nerve in the chest that controls breathing until other medical interventions are available or the patient recovers. The research will develop and validate the automated external respiration system for testing in human research participants and ultimately aims to develop a system usable in a community setting. |
||||||||
3R01DA057630-01S1
Show Summary |
Predicting Fatal and Non-Fatal Overdose in Los Angeles County with Rapid Overdose Surveillance Dashboard to Target Street-Based Addiction Treatment and Harm Reduction Services | Cross-Cutting Research | Increasing Participant Diversity, Inclusion, and Engagement in HEAL Research | NIDA | UNIVERSITY OF CALIFORNIA LOS ANGELES | SHOVER, CHELSEA LEIGH (contact); GOODMAN, DAVID | Los Angeles, CA | 2023 |
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
NOFO Number: PA-21-071 Summary: The International Classification of Diseases 10th revision codes are insufficient to accurately identify individuals who use opioids and stimulants together. This project will search already collected electronic health record data using a computer program to identify people with polysubstance use and determine what health care they receive. The research will improve understanding of polysubstance use in a region of Los Angeles, California, with very high rates of overdoses involving fentanyl and stimulants. |
||||||||
3UH3DA047700-05S2
Show Summary |
Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | MEBIAS DISCOVERY, INC | KUO, LAWRENCE C (contact); BARRETT, JAMES E | Philadelphia, PA | 2023 |
NOFO Title: Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders
NOFO Number: PA-20-272 Summary: There is an urgent need for a new generation of non-addictive, pain-relieving medications that do not cause problematic side effects like breathing problems or constipation. The overarching project is testing a new potential medication that interacts in a new way with the opioid system in human research participants. This supplement will help cover costs associated with the Safety Review Committee meeting required by the U.S. Food and Drug Administration. |
||||||||
1R61DA057629-01A1
Show Summary |
Chicago Data-driven OUD Screening, Engagement, Treatment and Planning (C-DOSETaP) System | Cross-Cutting Research | Translating Data 2 Action to Prevent Overdose | NIDA | UNIVERSITY OF ILLINOIS AT CHICAGO | KARNIK, NIRANJAN | Chicago, IL | 2023 |
NOFO Title: HEAL Initiative: HEAL Data2Action – Innovation and Acceleration Projects, Phased Awards (R61/R33, Clinical Trial Optional)
NOFO Number: RFA-DA-23-057 Summary: Health services for the treatment of opioid use disorder (OUD) are fragmented in west Chicago, an epicenter for overdose deaths. This project will develop a data-driven opioid response plan involving key partners. These include local health departments, community organizations, health care systems, and people with lived experience. The research will develop a digital screening tool for OUD that can be used in hospitals and their emergency departments. The tool will be built from machine learning of data from electronic health records, the prescription drug monitoring program, and patient-reported measures. The research will test the value of the screening tool for connecting people to treatment and preventing fatal overdoses mortality in local neighborhoods. |
||||||||
U01DA058548-01
Show Summary |
Clinical Development of a Therapeutic Agent for Rapid Reversal of Methamphetamine Intoxication | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | CLEAR SCIENTIFIC, LLC | LI, XINHUA | Cambridge, MA | 2023 |
NOFO Title: Grand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional)
NOFO Number: PAR-19-327 Summary: Currently there are no safe, rapidly acting treatments for methamphetamine use disorder and overdose. This project will evaluate a potential treatment: the small molecule CS-1103, which selectively attaches to methamphetamine in the blood. This molecule quickly removes methamphetamine blood and into urine for elimination from the body. The research will evaluate the safety and compatibility of CS-1103 with the human body, toward future clinical testing in humans. |
||||||||
1R01DA058621-01
Show Summary |
Optimizing Patient-Centered Opioid Tapering with Mindfulness-Oriented Recovery Enhancement (MORE) | Clinical Research in Pain Management | Reducing Opioid-Related Harms to Treat Chronic Pain (IMPOWR and MIRHIQL) | NIDA | UNIVERSITY OF UTAH | GARLAND, ERIC LEE (contact); COOPERMAN, NINA | Salt Lake City, UT | 2023 |
NOFO Title: HEAL Initiative: Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL) (R01 Clinical Trial Required)
NOFO Number: RFA-DA-23-041 Summary: Decreasing opioid dosing faster than advised by clinical recommendations often leaves chronic pain unaddressed and may increase the risk of overdose and suicide compared to continuing long-term opioid treatment. This project will compare a patient-centered tapering protocol with or without MORE in primary care offices in New Jersey and Utah. The MORE approach integrates training in mindfulness, reappraisal, and savoring to alter behavior away from valuation of drug rewards and toward natural rewards. This research will also identify practices to use MORE in primary care settings. |
||||||||
1UG3DA058553-01
Show Summary |
Development of Sigma Receptor/DAT Dual-Targeting Compounds to Treat Stimulant Use Disorder | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | SPARIAN BIOSCIENCES, INC. | REICH, JEFFREY | New York, NY | 2023 |
NOFO Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
NOFO Number: PAR-20-092 Summary: An increasing number of Americans use multiple drugs at the same time, and overdose deaths from stimulants have increased. However, there are no available treatments for stimulant use disorder. This project aims to develop new treatment (SBS-518) for cocaine use disorder. Previous research using animal models showed that SBS-518 decreases stimulant self-administration without being rewarding itself. The research will continue the development of SBS-518 toward testing in human research participants. |
||||||||
1UG3DA056247-01
Show Summary |
Phase 1 and 2 Studies of Sublingual Dexmedetomidine, an Alpha 2 Adrenergic Agonist, for Treating Opioid Withdrawal | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | NEW YORK STATE PSYCHIATRIC INSTITUTE dba RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC | LEVIN, FRANCES RUDNICK | New York, NY | 2022 |
NOFO Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
NOFO Number: PAR-20-092 Summary: Withdrawal symptoms associated with current opioid use disorder treatments, such as naltrexone or buprenorphine, can be serious obstacles to successful treatment. This project aims to develop a U.S. Food and Drug Administration-approved sedative medication (dexmedetomidine) as an under-the-tongue film to treat opioid withdrawal symptoms at doses that have minimal ill effects on blood pressure and heart rate. This research will compare the safety and efficacy of dexmedetomidine to lofexidine, which is currently approved to treat opioid withdrawal. |
||||||||
1UG3DA053094-01A1
Show Summary |
The Development of Delta Opioid Receptor Agonists for the Treatment of Opioid Withdrawal Associated Behaviors | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | UNIVERSITY OF ILLINOIS AT CHICAGO | PRADHAN, AMYNAH AMIR ALI | Chicago, IL | 2022 |
NOFO Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
NOFO Number: PAR-20-092 Summary: This project aims to develop a new way to stimulate the delta opioid receptor to treat withdrawal and abstinence from chronic opioid use. Withdrawal can cause pain, depression, and anxiety, which contribute to relapse. The research will test promising drug candidates in animal models with the intention of bringing at least one effective and safe compound to the final stage of drug development before human clinical trials can begin. |
||||||||
1R01DA057605-01
Show Summary |
Rapid Actionable Data for Opioid Response in Kentucky (RADOR-KY) | Cross-Cutting Research | Leveraging Existing and Real-Time Opioid and Pain Management Data | NIDA | UNIVERSITY OF KENTUCKY | SLAVOVA, SVETLA STEFANOVA (contact); TALBERT, JEFFERY C | Lexington, KY | 2022 |
NOFO Title: HEAL Initiative: Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R01- Clinical Trial Not Allowed)
NOFO Number: RFA-DA-22-044 Summary: To respond quickly and effectively to the constantly changing dynamics of the opioid crisis, public health agencies and organizations need timely state and local data to make critical decisions about where to allocate resources and target responses. This project creates the Rapid Actionable Data for Opioid Response in Kentucky system, a near real-time statewide surveillance system. This resource will combine data from multiple state agencies to provide actionable and timely information to support opioid overdose prevention, harm reduction, evidence-based treatment, and recovery services. The project will also develop user-driven reporting and visualization tools (mobile and web-based apps) that provide immediate access to near real-time community or state level data, reports, and visual analytics. |
||||||||
1R01DA057613-01
Show Summary |
Assessing the Reach, Effectiveness, and Implementation of Multiple Harm Reduction Interventions | Translation of Research to Practice for the Treatment of Opioid Addiction | Harm Reduction Approaches to Reduce Overdose Deaths | NIDA | RESEARCH TRIANGLE INSTITUTE | KRAL, ALEXANDER H | Research Triangle Park, NC | 2022 |
NOFO Title: HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional)
NOFO Number: RFA-DA-22-046 Summary: Numerous harm reduction strategies are available to reduce the harmful consequences of drug use. Examples include syringe services programs that provide sterile syringes, easy access to naloxone, and fentanyl test strips that may help people identify whether the substance(s) they plan to take contain fentanyl. This project aims to evaluate the use and effectiveness of several strategies in an urban environment as well as determine the openness and commitment of providers to offering them. |
||||||||
1R21DA057598-01
Show Summary |
Tracking the Opioid Epidemic with Social Media: An Early Warning System | Cross-Cutting Research | Leveraging Existing and Real-Time Opioid and Pain Management Data | NIDA | STANFORD UNIVERSITY | ALTMAN, RUSS BIAGIO | Redwood City, CA | 2022 |
NOFO Title: HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R21- Clinical Trial Not Allowed)
NOFO Number: RFA-DA-22-045 Summary: A key component to addressing the current opioid overdose crisis is the ability to track dangerous opioid use in a timely manner so that public health agencies can plan accordingly. Direct reports about drug use and overdoses from social media might provide a useful early warning system that when combined with other sources, can provide policy makers and public health officials with powerful tools for monitoring this public health crisis. This project will explore the usefulness of Twitter and Reddit as a social media component of opioid use surveillance – in particular by monitoring mentions of fentanyl and synthetic opioids at various geographic levels (e.g., local or regional) and over time. |
||||||||
1R01DA057682-01
Show Summary |
A Network-Based, Mixed Methods Study to Identify and Support Multiple Overdose Responders and Inform Overdose Prevention Interventions | Translation of Research to Practice for the Treatment of Opioid Addiction | Harm Reduction Approaches to Reduce Overdose Deaths | NIDA | UNIVERSITY OF NEVADA RENO | WAGNER, KARLA D | Reno, NV | 2022 |
NOFO Title: HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional)
NOFO Number: RFA-DA-22-046 Summary: While some people who use drugs do not carry or use naloxone, others respond to multiple overdoses over short periods of time. This project aims to identify characteristics and experiences of these individuals, known as “overdose responders,” toward better understanding barriers to naloxone use. The research will also test interventions to support the well-being of responders and to increase the number of community members ready and willing to give naloxone to reverse overdose. |
||||||||
1R01DA057686-01
Show Summary |
Fast and Fine: NLP Methods for Near Real-Time and Fine-Grained Overdose Surveillance | Cross-Cutting Research | Leveraging Existing and Real-Time Opioid and Pain Management Data | NIDA | UNIVERSITY OF KENTUCKY | KAVULURU, VENKATA NAGA RAMAKANTH | Lexington, KY | 2022 |
NOFO Title: HEAL Initiative: Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R01- Clinical Trial Not Allowed)
NOFO Number: RFA-DA-22-044 Summary: Timely and accurate surveillance of fatal and non-fatal overdoses is necessary in light of the worsening overdose crisis, but data is rarely available in real-time. Tracking non-fatal overdoses is especially important because patients who overdose once are likely to experience additional and potentially fatal overdoses. This project aims to increase the quality and timeliness of non-fatal overdose data estimates by analyzing clinicians’ notes rather than clinical codes from emergency department and emergency medical services records. The datasets and models produced from this research will be used to build an interactive dashboard with up-to-date, county-level overdose-surveillance estimates for use by Kentucky first responders to aid in rapid allocation of resources. |
||||||||
1R01DA057651-01
Show Summary |
Culturally Response Integrated Harm Reduction Services for Black and Latinx People Who use Drugs | Translation of Research to Practice for the Treatment of Opioid Addiction | Harm Reduction Approaches to Reduce Overdose Deaths | NIDA | NEW YORK UNIVERSITY SCHOOL OF MEDICINE | JORDAN, AYANA | New York, NY | 2022 |
NOFO Title: HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional)
NOFO Number: RFA-DA-22-046 Summary: There has been a substantial increase in overdose deaths among Black and Hispanic/Latino people who use drugs. This project will test and evaluate delivery of harm reduction services from a mobile van. A community-based care coordinator will assess the specific needs of each participant (such as housing, food assistance, and mental health treatment) toward the goal of linking each person to appropriate services. |
||||||||
1R24DA057611-01
Show Summary |
RTI HEAL Harm Reduction Network Coordination Center | Translation of Research to Practice for the Treatment of Opioid Addiction | Harm Reduction Approaches to Reduce Overdose Deaths | NIDA | RESEARCH TRIANGLE INSTITUTE | OGA, EMMANUEL AJA (contact); CANCE, JESSICA DUNCAN | Research Triangle Park, NC | 2022 |
NOFO Title: HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders: Coordination Center (R24 Clinical Trial Optional)
NOFO Number: RFA-DA-22-042 Summary: This project creates the HEAL Harm Reduction Network Coordination Center, which will provide support to the nine research studies in the HEAL Harm Research Reduction Network. The center will provide administrative and logistical help; support data harmonization and data sharing; involve stakeholders in all network activities; and share research findings and other products with researchers, practitioners, stakeholders, and the general public. |
||||||||
1R01DA057685-01
Show Summary |
Identifying Suspected Drug Overdose Deaths in Near Real-Time Using Data Collected by Death Investigators | Cross-Cutting Research | Leveraging Existing and Real-Time Opioid and Pain Management Data | NIDA | FRIENDS RESEARCH INSTITUTE, INC. | HOCHSTATTER, KARLI RAE | Baltimore, MD | 2022 |
NOFO Title: HEAL Initiative: Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R01- Clinical Trial Not Allowed)
NOFO Number: RFA-DA-22-044 Summary: Effective responses to the highly dynamic overdose crisis require accurate and timely information about the timing and location of drug overdoses, which is currently reported mainly through death certificates that take time to become available and thus limit life-saving responses. This project will comprehensively evaluate, optimize, and assess barriers and facilitators to adoption of a surveillance tool developed by the New York City Office of the Chief Medical Examiner. The tool uses data routinely collected during death investigations to predict in near real-time whether a death was due to an unintentional drug overdose. The findings will inform drug overdose mortality surveillance efforts in other states. |
||||||||
1R01DA057665-01
Show Summary |
Promoting Remote Harm Reduction and Secondary Services in Rural Settings (PROMOTE) Study | Translation of Research to Practice for the Treatment of Opioid Addiction | Harm Reduction Approaches to Reduce Overdose Deaths | NIDA | UNIVERSITY OF CHICAGO | PHO, MAI TUYET (contact); MACKESY-AMITI, MARY ELLEN | Chicago, IL | 2022 |
NOFO Title: HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional)
NOFO Number: RFA-DA-22-046 Summary: Access to harm reduction services are often limited in rural areas. Secondary distribution is a potentially promising strategy for rural areas that involves people sharing harm reduction supplies such as naloxone or fentanyl test strips with other people who use drugs that do not come into contact with harm reduction service providers. This project aims to examine drug use and use of harm reduction services among people in rural communities, as well as highlight factors that make people more or less likely to use secondary distribution approaches. |
||||||||
1R21DA057677-01
Show Summary |
Developing a Timely Opioid Overdose Detection Tool through a Tribally Engaged Approach | Cross-Cutting Research | Leveraging Existing and Real-Time Opioid and Pain Management Data | NIDA | UNIVERSITY OF CALIFORNIA, SAN DIEGO | GAINES, TOMMI LYNN | La Jolla, CA | 2022 |
NOFO Title: HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R21- Clinical Trial Not Allowed)
NOFO Number: RFA-DA-22-045 Summary: Addressing the current opioid overdose crisis requires tracking risky opioid use in a timely manner so that public health agencies can plan accordingly and supply life-saving resources. American Indian Tribes often lack such tools, even though American Indians and Alaska Natives have the highest rates of opioid overdose fatalities. This project will adapt commercialized monitoring technologies for use in Tribal communities, in consultation with affected Tribes. Through a partnership with a Tribal Fire Department and a software company providing data analytics for public safety agencies, this research will build a near real-time opioid overdose dashboard for use within Tribal boundaries. The findings may also improve data collection and outbreak monitoring for other substances, including methamphetamine and cocaine. |
||||||||
1R01DA057645-01
Show Summary |
Mobile Health Strategies to Support Longitudinal Engagement in Harm Reduction Services | Translation of Research to Practice for the Treatment of Opioid Addiction | Harm Reduction Approaches to Reduce Overdose Deaths | NIDA | UNIVERSITY OF WISCONSIN-MADISON | WESTERGAARD, RYAN PATRICK (contact); SEAL, DAVID W | Madison, WI | 2022 |
NOFO Title: HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional)
NOFO Number: RFA-DA-22-046 Summary: Research is needed to better understand how to make life-saving harm reduction services more accessible to populations that are hard to reach. This project will identify the physical and psychological factors that make harm reduction services most effective. The findings will then be used to inform the development, implementation, and testing of an innovative strategy consisting of several internet- and smartphone-based tools designed to improve access to harm reduction services for people who are hard to reach. |
||||||||
1R01DA057630-01
Show Summary |
Predicting Fatal and Non-Fatal Overdose in Los Angeles County with Rapid Overdose Surveillance Dashboard to Target Street-Based Addiction Treatment and Harm Reduction Services | Cross-Cutting Research | Leveraging Existing and Real-Time Opioid and Pain Management Data | NIDA | UNIVERSITY OF CALIFORNIA LOS ANGELES | SHOVER, CHELSEA LEIGH (contact); GOODMAN, DAVID | Los Angeles, CA | 2022 |
NOFO Title: HEAL Initiative: Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R01- Clinical Trial Not Allowed)
NOFO Number: RFA-DA-22-044 Summary: Effective overdose prevention requires timely, location-specific data to efficiently direct resources and interventions as well as to inform healthcare policy. However, rarely is such information available, resulting in responses that are frequently too late. This project will partner with local government agencies from Los Angeles County, California, to rapidly acquire and analyze information in near real-time from multiple sources to identify overdose hotspots and determine overdose metrics. This information will be used to develop a publicly available Rapid Overdose Surveillance Los Angeles online dashboard with built-in analytics. The dashboard will help determine the scope and specifics of overdose and opioid use in Los Angeles County to help target response and guide mobile addiction treatment and harm reduction services. |
||||||||
1R01DA057670-01
Show Summary |
Peer Engagement in Methamphetamine Harm-Reduction with Contingency Management (PEER-CM) | Translation of Research to Practice for the Treatment of Opioid Addiction | Harm Reduction Approaches to Reduce Overdose Deaths | NIDA | OREGON HEALTH & SCIENCE UNIVERSITY | KORTHUIS, PHILIP TODD | Portland, OR | 2022 |
NOFO Title: HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional)
NOFO Number: RFA-DA-22-046 Summary: Despite substantial increases in overdose deaths among people who use methamphetamine, little is known about how to effectively provide harm reduction services to these individuals. This project will combine and test two harm reduction interventions for people who use methamphetamine. First, peer recovery support specialists will help identify personal harm reduction goals. The project will also test the value of incentives toward achieving these goals (a strategy known as contingency management). |